SCHEMBL2646552

SCHEMBL2646552

Cc1cc(S)ccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18633351 0.74
SCHEMBL28064604 0.72 CCR1 (0.48)
SCHEMBL28381757 0.72 UHRF1 (1.00)
SCHEMBL44068 0.72
SCHEMBL6363027 0.72
SCHEMBL29365333 0.72
SCHEMBL30308690 0.72 DYRK1A (0.65)
SCHEMBL1896511 0.72 DYRK1A (0.65)
SCHEMBL17377386 0.70
Bromide SCHEMBL5327604 0.70 UHRF1 (0.94)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117693214-A Quantum dot light-emitting device, preparation method thereof and display device 广东聚华印刷显示技术有限公司 2024-03-12 CN claimed
US-20250101003-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2025-03-27 US disclosed
EP-4436661-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS Lario Therapeutics Limited (GB) 2024-10-02 EP disclosed
CN-117693214-A Quantum dot light-emitting device, preparation method thereof and display device 广东聚华印刷显示技术有限公司 2024-03-12 CN disclosed
WO-2023205595-A2 EGFR INHIBITORS IN CANCER TREATMENT CELYN THERAPEUTICS, INC (US) 2023-10-26 WO disclosed
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
WO-2023125737-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF SILEXON AI TECHNOLOGY CO., LTD. (CN) 2023-07-06 WO disclosed
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-01 US disclosed
WO-2023094827-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed
EP-3185865-B1 TETRAHYDRONAPTHTYRIDINE DERIVATIVES AS MGLUR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE. MERCK SHARP & DOHME (US) 2020-07-15 EP disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed
CN-1249003-C Bisphenol compound composition having excellent thermal stability MITSUBISHI CHEM CORP (JP) 2006-04-05 CN disclosed
CN-1494522-A Bisphenol compound composition having excellent thermal stability 三菱化学株式会社 2004-05-05 CN disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
US-4482663-A Rubber compositions comprising a siliceous filler in combination with an organosulfur substituted pyridine promotor PHILLIPS PETROLEUM COMPANY (US) 1984-11-13 US disclosed
US-3966741-A Process for the preparation of substituted or unsubstituted 4-pyridylthioacetic acid OCE-ANDENO B.V. (NL) 1976-06-29 US disclosed
US-3956345-A POLYESTER CIBA-GEIGY AG (CH) 1976-05-11 US disclosed